Show simple item record

dc.contributor.authorPanek, R
dc.contributor.authorWelsh, L
dc.contributor.authorDunlop, A
dc.contributor.authorWong, KH
dc.contributor.authorRiddell, AM
dc.contributor.authorKoh, D-M
dc.contributor.authorSchmidt, MA
dc.contributor.authorDoran, S
dc.contributor.authorMcquaid, D
dc.contributor.authorHopkinson, G
dc.contributor.authorRichardson, C
dc.contributor.authorNutting, CM
dc.contributor.authorBhide, SA
dc.contributor.authorHarrington, KJ
dc.contributor.authorRobinson, SP
dc.contributor.authorNewbold, KL
dc.contributor.authorLeach, MO
dc.date.accessioned2020-06-22T15:47:20Z
dc.date.issued2016-07
dc.identifier.citationJournal of magnetic resonance imaging : JMRI, 2016, 44 (1), pp. 72 - 80
dc.identifier.issn1053-1807
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3763
dc.identifier.eissn1522-2586
dc.identifier.doi10.1002/jmri.25134
dc.description.abstractPurpose To determine whether quantitation of T2* is sufficiently repeatable and sensitive to detect clinically relevant oxygenation levels in head and neck squamous cell carcinoma (HNSCC) at 3T.Materials and methods Ten patients with newly diagnosed locally advanced HNSCC underwent two magnetic resonance imaging (MRI) scans between 24 and 168 hours apart prior to chemoradiotherapy treatment. A multiple gradient echo sequence was used to calculate T2* maps. A quadratic function was used to model the blood transverse relaxation rate as a function of blood oxygenation. A set of published coefficients measured at 3T were incorporated to account for tissue hematocrit levels and used to plot the dependence of fractional blood oxygenation (Y) on T2* values, together with the corresponding repeatability range. Repeatability of T2* using Bland-Altman analysis, and calculation of limits of agreement (LoA), was used to assess the sensitivity, defined as the minimum difference in fractional blood oxygenation that can be confidently detected.Results T2* LoA for 22 outlined tumor volumes were 13%. The T2* dependence of fractional blood oxygenation increases monotonically, resulting in increasing sensitivity of the method with increasing blood oxygenation. For fractional blood oxygenation values above 0.11, changes in T2* were sufficient to detect differences in blood oxygenation greater than 10% (Δ T2* > LoA for ΔY > 0.1).Conclusion Quantitation of T2* at 3T can detect clinically relevant changes in tumor oxygenation within a wide range of blood volumes and oxygen tensions, including levels reported in HNSCC. J. Magn. Reson. Imaging 2016;44:72-80.
dc.formatPrint-Electronic
dc.format.extent72 - 80
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectCarcinoma, Squamous Cell
dc.subjectHead and Neck Neoplasms
dc.subjectOxygen
dc.subjectImage Interpretation, Computer-Assisted
dc.subjectObserver Variation
dc.subjectMagnetic Resonance Imaging
dc.subjectSensitivity and Specificity
dc.subjectReproducibility of Results
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectBiomarkers, Tumor
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.titleRepeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T.
dc.typeJournal Article
dcterms.dateAccepted2015-12-02
rioxxterms.versionofrecord10.1002/jmri.25134
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of magnetic resonance imaging : JMRI
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume44
pubs.embargo.termsNot known
icr.researchteamMagnetic Resonanceen_US
icr.researchteamPre-Clinical MRIen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen
dc.contributor.icrauthorLeach, Martinen
dc.contributor.icrauthorRobinson, Simonen
dc.contributor.icrauthorDoran, Simonen
dc.contributor.icrauthorKoh, Dow-Muen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0